EJNMMI Research最新文献

{"title":"⁶⁸Ga-Pentixafor PET/CT for the assessment of therapeutic outcomes following superselective adrenal arterial embolization in patients with primary aldosteronism.","authors":"MengDan Li, Lili Guan, Lu Yang, WenBo Li, Zhu Xia, Min Mao, Hua Pang","doi":"10.1186/s13550-024-01194-3","DOIUrl":"10.1186/s13550-024-01194-3","url":null,"abstract":"<p><strong>Background: </strong>Superselective adrenal artery embolization (SAAE) represents a novel therapeutic strategy for managing primary aldosteronism (PA). Currently, the evaluation of its efficacy is primarily restricted to clinical indicators, with a notable deficiency in imaging evaluation methodologies. In recent years, several studies have investigated the application of ⁶⁸Ga-Pentixafor PET/CT for the classification of PA. However, there is a scarcity of specific research investigating the role of PET/CT in the evaluation of efficacy of this condition. Consequently, this study aims to evaluate the therapeutic efficacy of SAAE in patients with PA using ⁶⁸Ga-Pentixafor PET/CT, with the objective of establishing imaging evaluation methodologies for assessing PA patients post-SAAE treatment.</p><p><strong>Results: </strong>Of the 27 patients, 2 achieved complete clinical remission, while 25 experienced partial remission. Biochemically, 13 patients attained complete remission, 13 had partial remission, and 1 did not. For patients with aldosterone-producing adenoma, both visual and semi-quantitative analyses of PET/CT effectively assessed changes in radioactive uptake of the lesion. For idiopathic hyperaldosteronism patients, PET/CT parameters were more effective than visual analysis in evaluating SAAE efficacy. A significant difference in the ΔTLR-40 min parameter was observed across biochemical outcomes (P = 0.041), with patients having ΔTLR-40 min ≥ 0.07 showing better outcomes (AUC = 0.789, P = 0.041).</p><p><strong>Conclusions: </strong>⁶⁸Ga-Pentixafor PET/CT enables timely assessment of therapeutic outcomes in patients with PA following SAAE, thereby improving clinical decision-making and patient management.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"5"},"PeriodicalIF":3.1,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy.","authors":"Jan Heilinger, Katrin Sabine Roth, Henning Weis, Antonis Fink, Jasmin Weindler, Felix Dietlein, Philipp Krapf, Klaus Schomäcker, Bernd Neumaier, Markus Dietlein, Alexander Drzezga, Carsten Kobe","doi":"10.1186/s13550-024-01190-7","DOIUrl":"10.1186/s13550-024-01190-7","url":null,"abstract":"<p><strong>Background: </strong>In clinical practice, several radiopharmaceuticals are used for PSMA-PET imaging, each with distinct biodistribution patterns. This may impact treatment decisions and outcomes, as eligibility for PSMA-directed radioligand therapy is usually assessed by comparing tumoral uptake to normal liver uptake as a reference. In this study, we aimed to compare tracer uptake intraindividually in various reference regions including liver, parotid gland and spleen as well as the respective tumor-to-background ratios (TBR) of different ¹⁸F-labeled PSMA ligands to today's standard radiopharmaceutical ⁶⁸Ga-PSMA-11 in a series of patients with biochemical recurrence of prostate cancer who underwent a dual PSMA-PET examination as part of an individualized diagnostic approach.</p><p><strong>Results: </strong>Differences in background activity among different PSMA-PET tracers lead to variations in tumor-to-background ratios (TBR). In [¹⁸F]F-DCFPyL-PET, TBR with the liver as the reference organ (TBR_liver) was comparable to [⁶⁸Ga]Ga-PSMA-11-PET, while [¹⁸F]F-PSMA-1007-PET and [¹⁸F]F-JK-PSMA-7-PET showed significantly lower values. Using the parotid gland as the reference (TBR_parotidgland), [¹⁸F]F-DCFPyL-PET exhibited significantly higher values, whereas [¹⁸F]F-PSMA-1007-PET and [¹⁸F]F-JK-PSMA-7-PET were comparable. For the spleen (TBR_spleen), [¹⁸F]F-JK-PSMA-7-PET was comparable, but [¹⁸F]F-DCFPyL-PET and [¹⁸F]F-PSMA-1007-PET showed significantly higher and lower values, respectively. An additional Bland-Altman analyses revealed low bias for [¹⁸F]F-DCFPyL-PET in TBR_parotidgland, whereas significant differences in TBR_liver and TBR_spleen for the other tracers resulted in higher bias.</p><p><strong>Conclusion: </strong>Different PSMA-PET tracers exhibit distinct biodistribution patterns, leading to variations in tumor-to-background ratios (TBR) in reference organs such as the liver, parotid gland, and spleen. Patient selection for PSMA-directed radioligand therapy is currently based on a semiquantitative approach using the liver as a reference region in [⁶⁸Ga]Ga-PSMA-11-PET. Thus, the use of alternative [¹⁸F]-labeled tracers may result in under- or overestimation of a patient's suitability for therapy. This highlights the importance of a comprehensive understanding of the differences in tracer-specific uptake behavior for accurate decisions regarding PSMA-expression levels. However, as the patient cohort in this study is at earlier disease stages, the generalizability of these findings to later-stage patients remains unclear and requires further investigation.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"4"},"PeriodicalIF":3.1,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11723865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Quantification of [^99mTc]Tc-HDP bone SPECT/CT: can we improve the body weight based standardized uptake value with a more robust normalization?","authors":"Tiberiu Damian, Noel Spielhofer, Jakob Heimer, Alexander W Sauter, Cristina Popescu, Daniel Hausmann, Jason L Manser, Karim Eid, Rahel A Kubik-Huch, Irene A Burger","doi":"10.1186/s13550-024-01192-5","DOIUrl":"10.1186/s13550-024-01192-5","url":null,"abstract":"","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"3"},"PeriodicalIF":3.1,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatobiliary scintigraphy and liver function changes in patients with hepatocellular carcinoma treated with ¹⁶⁶Ho-radioembolization : HBS in HCC treated with holmium-166.","authors":"Margot T M Reinders, Maarten J L Smits, Karel van Erpecum, Joep de Bruijne, Rutger C G Bruijnen, Dave Sprengers, Rob de Man, Erik Vegt, Jan N M IJzermans, Marnix G E H Lam, Arthur J A T Braat","doi":"10.1186/s13550-025-01196-9","DOIUrl":"10.1186/s13550-025-01196-9","url":null,"abstract":"<p><strong>Background: </strong>To study the feasibility of hepatobiliary scintigraphy (HBS) to improve selection and planning of patients with hepatocellular carcinoma (HCC) treated with holmium-166 (¹⁶⁶Ho)-microspheres radioembolization.</p><p><strong>Results: </strong>Thirty-one patients with HCC were included and treated with ¹⁶⁶Ho- radioembolization as part of a prospective phase 2 study. Twenty-seven patients were eligible for analysis, 67% had a cirrhotic liver morphology on imaging, 70% had multifocal disease and 51% had bilobar disease. None of the patients had clinical signs of liver decompensation (Child Pugh ≤ B7, median MELD 9 or ALBI - 2.55). Global and regional hepatic function was based on manual delineation of HBS using 200 MBq ^99mTc-mebrofenine, acquired during screening and approximately three months after ¹⁶⁶Ho-radioembolization, referred to as liver clearance rate (LCR). In line with LCR at baseline, a significant correlation was found between LCR and lab results, including bilirubin, albumin, ALT, MELD-score, and ALBI-score (p < 0.05) during follow-up. HBS showed a significant decrease in median LCR (-16%; p = 0.0017) and volume (-17%; p = 0.0027) in the treated liver, without a significant increase in the non-treated liver. Median relative change in overall LCR in non-cirrhotics was 0% (range - 23-33%), in cirrhotics - 10% (range - 40 - 19%; p = 0.40).</p><p><strong>Conclusion: </strong>HBS showed that hepatic function and volume significantly decreased in parts of the liver treated with ¹⁶⁶Ho-microspheres radioembolization in patients with HCC. Cirrhotic patients do not seem to have the capacity to increase hepatic function in the treated part of the liver.</p><p><strong>Trial registration: </strong>Registry name: Clinicaltrials.gov.</p><p><strong>Trial number: </strong>NCT03379844. Date of registration: 21 November 2017. Trial URL: https://clinicaltrials.gov/study/NCT03379844?cond=hcc&term=hepar primary&rank=1#study-overview .</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"2"},"PeriodicalIF":3.1,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing cutoff values for visual amyloid positivity in [¹⁸F]flutemetamol PET.","authors":"Yong-Jin Park, So Young Moon, Joon-Kee Yoon, Su-Jin Lee, Young-Sil An","doi":"10.1186/s13550-024-01193-4","DOIUrl":"10.1186/s13550-024-01193-4","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to establish the optimal cutoff values for visual amyloid positivity using standardized uptake value ratios (SUVRs) in [¹⁸F]flutemetamol (FMM) positron emission tomography (PET) imaging. Given the variability in amyloid assessment, our goal was to determine cutoff values that enhance diagnostic accuracy and assist clinicians in reliably identifying amyloid positivity.</p><p><strong>Results: </strong>The identified cutoff values for visual amyloid positivity were > 1.6 for the cerebellar gray matter, > 1.38 for the whole cerebellum, and > 0.63 for the pons, yielding high sensitivity (95.5%, 94.5%, and 95.8%, respectively) and specificity (91.2%, 94.3%, and 95.2%, respectively).</p><p><strong>Conclusions: </strong>The SUVR cutoff values demonstrated excellent diagnostic performance, supporting their clinical use in assessing visual amyloid positivity in [¹⁸F]FMM PET imaging.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"15 1","pages":"1"},"PeriodicalIF":3.1,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biodistribution and dosimetry of the PET radioligand [¹⁸F]CHDI-650 in mice for detection of mutant huntingtin aggregates.","authors":"Jordy Akkermans, Alan Miranda, Jeroen Verhaeghe, Filipe Elvas, Franziska Zajicek, Jonathan Bard, Longbin Liu, Vinod Khetarpal, Robert Doot, Steven Staelens, Daniele Bertoglio","doi":"10.1186/s13550-024-01188-1","DOIUrl":"10.1186/s13550-024-01188-1","url":null,"abstract":"<p><strong>Background: </strong>Huntington's disease (HD) is a rare neurodegenerative disorder caused by an expansion of the CAG trinucleotide repeat in the huntingtin gene which encodes the mutant huntingtin protein (mHTT) that is associated with HD-related neuropathophysiology. Noninvasive visualization of mHTT aggregates in the brain, with positron emission tomography (PET), will allow to reliably evaluate the efficacy of therapeutic interventions in HD. This study aimed to assess the radiation burden of [¹⁸F]CHDI-650, a novel fluorinated mHTT radioligand, in humans based on both in vivo and ex vivo biodistribution in mice and subsequent determination of dosimetry for dosing in humans.</p><p><strong>Results: </strong>Wild-type male and female CD-1 Swiss mice (n = 15/sex) were used to assess in vivo PET imaging-based and ex vivo biodistribution-based tracer distribution of [¹⁸F]CHDI-650 at 30-, 60-, 120-, 240- and 360-min post-injection. Three-dimensional volumes of interest of the organs were drawn on the co-registered PET/CT image and organs were collected after dissection. Organ radioactivity levels were determined using both modalities. The residence time was calculated and extrapolated to human phantoms. The absorbed and effective doses were computed with OLINDA/EXM 2.2 and IDAC-Dose2.1. Ex vivo and PET-imaging biodistribution of [¹⁸F]CHDI-650 showed rapid washout after 30 min in most of the organs with the highest uptake in the gallbladder and urine in mice. Extrapolation of the data to human phantoms with OLINDA showed a total mean in vivo based effective dose of 21.7 μSv/MBq with the highest equivalent organ dose in the urinary bladder wall (4.52 μSv/MBq). The total mean ex vivo based effective dose was calculated to be 20.6 μSv/MBq. The highest equivalent organ dose ex vivo in the urinary bladder wall was estimated to be 4.22 μSv/MBq. The predicted exposure in humans using IDAC-Dose correlated well to those obtained with OLINDA for both in vivo and ex vivo measurements (r = 0.9320 and r = 0.9368, respectively).</p><p><strong>Conclusions: </strong>Dosimetry analysis indicated absorbed and effective doses of [¹⁸F]CHDI-650 are well below the recommended limits, suggesting that the radioligand is suitable for clinical assessment. Based on the highest effective dose estimates, an injection of 370 MBq in humans would result in a radiation dose of 8.03 mSv.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"126"},"PeriodicalIF":3.1,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discrimination of benign, atypical, and malignant peripheral nerve sheath tumours in neurofibromatosis type 1 - intraindividual comparison of positron emission computed tomography and diffusion-weighted magnetic resonance imaging.","authors":"Inka Ristow, Ivayla Apostolova, Michael G Kaul, Maria Stark, Antonia Zapf, Marie-Lena Schmalhofer, Victor F Mautner, Said Farschtschi, Gerhard Adam, Peter Bannas, Johannes Salamon, Lennart Well","doi":"10.1186/s13550-024-01189-0","DOIUrl":"10.1186/s13550-024-01189-0","url":null,"abstract":"<p><strong>Background: </strong>To intraindividually compare the diagnostic performance of positron emission computed tomography (F-18-FDG-PET/CT) and diffusion-weighted magnetic resonance imaging (DW-MRI) in a non-inferiority design for the discrimination of peripheral nerve sheath tumours as benign (BPNST), atypical (ANF), or malignant (MPNST) in patients with neurofibromatosis type 1 (NF1).</p><p><strong>Results: </strong>In this prospective single-centre study, thirty-four NF1 patients (18 male; 30 ± 11 years) underwent F-18-FDG-PET/CT and multi-b-value DW-MRI (11 b-values 0 - 800 s/mm²) at 3T. Sixty-six lesions corresponding to 39 BPNST, 11 ANF, and 16 MPNST were evaluated. Two radiologists independently assessed the maximum standardized uptake value (SUV_max) and mean and minimum apparent diffusion coefficient (ADC_mean/min) as well as the ADC in areas of lowest signal intensity in each lesion (ADC_dark). The AUCs of DW-MRI and F-18-FDG-PET/CT were compared to determine whether the ADC is non-inferior to SUV_max (non-inferiority margin equal to -10%). Follow-up of ≥ 24 months (BPNST) or histopathological evaluation (MPNST + ANF) served as diagnostic reference standard. Both SUV_max and ADC parameters demonstrated good diagnostic accuracy (AUC_SUVmax 94.0%; AUC_{ADCmean/min/dark} 91.6% / 90.1% / 92.5%). However, non-inferiority could not be demonstrated for any of the three ADC parameters (lower limits of the confidence intervals of the difference between the AUC of ADC_{mean/min/dark} and SUV_max -12.9% / -14.5% / -11.6%). Inter-rater reliability was excellent for both imaging techniques (Krippendorff's alpha all > 0.94).</p><p><strong>Conclusions: </strong>Both PET/CT-derived SUV_max and MRI-derived ADC allow sensitive and non-invasive differentiation of benign and (pre)-malignant peripheral nerve sheath tumours. Nevertheless, DW-MRI cannot be considered as non-inferior to F-18-FDG-PET/CT in this prospective single-centre study.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"127"},"PeriodicalIF":3.1,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11680535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro and ex vivo evaluation of preclinical models for FAP-targeted theranostics: differences and relevance for radiotracer evaluation.","authors":"Circe D van der Heide, Joana D Campeiro, Eline A M Ruigrok, Lilian van den Brink, Shashikanth Ponnala, Shawn M Hillier, Simone U Dalm","doi":"10.1186/s13550-024-01191-6","DOIUrl":"10.1186/s13550-024-01191-6","url":null,"abstract":"<p><strong>Background: </strong>Fibroblast activation protein (FAP) is an attractive target for cancer theranostics. Although FAP-targeted nuclear imaging demonstrated promising clinical results, only sub-optimal results are reported for targeted radionuclide therapy (TRT). Preclinical research is crucial in selecting promising FAP-targeted radiopharmaceuticals and for obtaining an increased understanding of factors essential for FAP-TRT improvement. FAP is mainly expressed by cancer-associated fibroblasts in the tumor stroma and less on cancer cells themselves. Therefore, other (complex) factors impact FAP-TRT efficacy compared to currently clinically applied TRT strategies. For accurate evaluation of these aspects, selection of a representative preclinical model is important. Currently mainly human cancer cell lines transduced to (over)express FAP are applied, lacking clinical representation. It is unclear how these and more physiological FAP-expressing models compare to each other, and whether/how the model influences the study outcome. We aimed to address this by comparing FAP tracer behavior in FAP-transduced HT1080-huFAP and HEK293-huFAP cells, and endogenous FAP-expressing U-87 MG cancer cells and PS-1 pancreatic stellate cells. [¹¹¹In]In-FAPI-46 and a fluorescent FAP-targeted tracer (RTX-1370S) were used to compare tracer binding/uptake and localization in vitro and ex vivo. Additionally, FAP expression was determined with RT-qPCR and anti-FAP IHC.</p><p><strong>Results: </strong>Although FAP expression was highest in HEK293-huFAP cells and cell line derived xenografts, this did not result in the highest tracer uptake. [¹¹¹In]In-FAPI-46 uptake was highest in HT1080-huFAP, closely followed by HEK293-huFAP, and a 6-10-fold lower uptake for U-87 MG and PS-1 cells. However, ex vivo U-87 MG xenografts only showed a 2-fold lower binding compared to HT1080-huFAP and HEK293-huFAP xenografts, mainly because the cell line attracts murine fibroblasts as demonstrated in our RT-qPCR and IHC studies.</p><p><strong>Conclusions: </strong>The interaction between FAP and FAP-targeted tracers differs between models, indicating the need for appropriate model selection and that comparing results across studies using different models is difficult.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"125"},"PeriodicalIF":3.1,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668701/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142880655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"cfDNA fragmentation patterns correlate with tumor burden measured via PSMA PET/CT volumetric parameters in patients with biochemical recurrence of prostate cancer.","authors":"Gary Amseian, Marcel Figueras, Joel Mases, Lourdes Mengual, Maria-Jose Ribal, Katherine Quintero, Rita Pages, Mercedes Ingelmo-Torres, Fiorella-Lizzeth Roldan, Rocío Caratini, David Fuster, Antonio Alcaraz, Laura Izquierdo, Pilar Paredes","doi":"10.1186/s13550-024-01170-x","DOIUrl":"10.1186/s13550-024-01170-x","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer recurrence following primary treatment poses a significant clinical challenge, particularly when detected through biochemical recurrence at low PSA levels. Conventional imaging modalities often fail to localize the disease at this early stage. PSMA PET has demonstrated superior sensitivity in detecting recurrent lesions, even in patients with low PSA. Concurrently, liquid biopsy, through analysis of cell-free DNA (cfDNA), offers a minimally invasive approach for monitoring disease. There is scarce evidence about the association between liquid biopsy and PSMA PET/CT findings. This study aimed to assess the correlation between liquid biopsy and tumor burden assessed by PSMA PET/CT in early recurring prostate cancer patients.</p><p><strong>Results: </strong>PSMA PET/CT and liquid biopsies of 32 patients in biochemical recurrence were analyzed. 12 patients (37.5%) had no PSMA PET-measurable disease. Four patients (12.5%) presented local recurrence, seven (21.9%) had recurrence in pelvic lymph nodes, one of whom also had local recurrence. Nine patients (28.1%) presented metastatic recurrence, with or without local or nodal recurrence. PSA levels correlated with molecular imaging data (p < 0.05), including whole body PSMA-TV, whole body PSMA-TL, whole body SUVmean and whole body SUVmax. The mean cfDNA fragment size fraction was inversely correlated with tumour burden measured with whole body PSMA-TV, with a Spearman correlation coefficient of -0.451 and a p-value of 0.009. No correlation was found between cfDNA concentration and PET-PSMA data.</p><p><strong>Conclusion: </strong>This prospective study demonstrated a statistically significant negative correlation between cfDNA fragmentation patterns and PSMA PET/CT volumetric parameters in patients with presumed localized prostate cancer with early biochemical recurrence. These findings underscore the potential of liquid biopsy as a biomarker and a complementary tool to PSMA PET/CT to assess disease progression during the follow-up of these patients.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"124"},"PeriodicalIF":3.1,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11655959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"P2X ₇-receptor binding in new-onset and secondary progressive MS - a [¹¹C]SMW139 PET study.","authors":"Jussi Lehto, Richard Aarnio, Jouni Tuisku, Marcus Sucksdorff, Esa Mikko Koivumäki, Marjo Nylund, Semi Helin, Johan Rajander, Jonathan Danon, Jayson Gilchrist, Michael Kassiou, Vesa Oikonen, Laura Airas","doi":"10.1186/s13550-024-01186-3","DOIUrl":"10.1186/s13550-024-01186-3","url":null,"abstract":"<p><strong>Background: </strong>PET imaging of activated microglia has improved our understanding of the pathology behind disability progression in MS, and pro-inflammatory microglia at 'smoldering' lesion rims have been implicated as drivers of disability progression. The P2X ₇R is upregulated in the cellular membranes of activated microglia. A single-tissue dual-input model was applied to quantify P2X ₇R binding in the normal appearing white matter, perilesional areas and thalamus among progressive MS patients, healthy controls and newly diagnosed relapsing MS patients.</p><p><strong>Results: </strong>Overall, tracer uptake in the MS brain was not significantly higher compared to HCs. In the 3 mm perilesional rim of all T1 lesions, tracer binding was higher among relapsing patients compared to progressive patients. Tracer binding was higher in males compared to females. Disease duration correlated with tracer binding in the normal appearing white matter. Age correlated negatively with tracer binding in the perilesional rims.</p><p><strong>Conclusions: </strong>Even as binding estimates obtained with the dual-input model were consistent with the expected distribution of P2X ₇Rs in the MS brain, the small free fraction of the parent tracer may limit its accuracy and applicability, and binding estimates between subjects were highly variable. Conclusive evidence for the applicability of [¹¹C]SMW139 to detect MS-related diffuse smoldering inflammation was not obtained.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"123"},"PeriodicalIF":3.1,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11621262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}